Video
Tarsus pipeline advances program for Demodex blepharitis
Author(s):
Last year, the company announced the data from the Saturn-1 study for TP-03, the first potential product to treat Demodex blepharitis, and the product is now in the phase 3 trial (Saturn-2). Aziz Mottiwala, chief commercial officer for Tarsus, gives a company update on the pipeline for their program for Demodex blepharitis.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
